Clinical trial · Observational
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
Prospective Study of Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas
NCT06089941CI-TRIAL-00103712PTCL-SEQactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess the feasibility of analyzing circulating tumor DNA (ctDNA) as a biomarker using the shallow whole genome sequencing (lpWGS) technique coupled with deep sequencing of a targeted panel of genes (NGS), in a population of patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphoma (PTCL).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Peripheral T Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| circulating tumoral DNA detection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Detection of circulating tumoral DNA
- description
- Blood assessment to detect circultating tumoral DNA
- interventionNames
- Other: circulating tumoral DNA detection
Primary outcomes (3)
- measure
- Feasibility of ctDNA assessement
- timeFrame
- at the inclusion
- description
- rate of patients considered informative (i.e. patient with at least one detectable mutation from ctDNA analysis by lpWGS and/or targeted NGS). The main objective will be achieved if the proportion of informative results is at least 90%.
- measure
- Feasibility of ctDNA assessement
- timeFrame
- 8 weeks
- description
- rate of patients considered informative (i.e. patient with at least one detectable mutation from ctDNA analysis by lpWGS and/or targeted NGS). The main objective will be achieved if the proportion of informative results is at least 90%.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 or over * Newly diagnosed or relapsed/refractory peripheral T-cell lymphoma (PTCL), including T/NK lymphoma (NKTL) * Pre-therapeutic FDG PET-CT already performed * Signed informed consent * Patients affiliated with or beneficiaries of a health insurance plan Exclusion Criteria: * Cutaneous T-cell lymphomas without systemic involvement * Pregnant or breastfeeding women * For newly diagnosed patients: patient who has already started the first systemic treatment for their lymphoma (apart from pre-phase corticosteroid therapy which is authorized) * For patients in a relapsed/refractory situation: Patient who has already started the new specific line of lymphoma treatment planned for the current relapsed/refractory situation (apart from pre-phase corticosteroid therapy which is authorized) * Lack of patient consent * Patient whose weight is less than 30 kg * Protected adult or deprived of freedoms (under guardianship or curatorship) * Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographic problem, etc.).
References
Publications (0)
Data not yet available
No reference posted for this study.